What Лайф 900 Treats: Main Uses and Benefits

The therapeutic application of this high-strength Hypericum perforatum extract is centered on providing support for emotional equilibrium and managing symptoms related to low moods and mental stress. Its use is recognized within therapeutic domains involving mild and moderate depressive symptoms.

The medicine is generally applied when a patient requires supportive symptomatic management for feelings of persistent sadness or emotional imbalance. This includes assisting with symptoms like listlessness, apathy, nervous tension, and mood-related sleep disturbances. It is relevant when supportive symptom management is appropriate for conditions characterized by increased discomfort or tension.

“The primary benefit is in easing the overall symptom load during difficult episodes, helping to restore a patient’s sense of vitality and daily comfort.”

It is commonly used across conditions presenting with episodic manifestations of mild or moderate depressive symptoms. It supports the patient during difficult phases by easing distress and contributes to a sense of stability when symptoms are more noticeable.

---

Quick Fact: Support for Mood Symptoms
Primary Focus	Mild to moderate depressive symptoms
Symptom Cluster	Low mood, listlessness, nervous tension
Context of Use	Common periods of emotional imbalance
Patient Benefit	Assists with functional stability

Regulatory References

1. NIH National Center for Complementary and Integrative Health

This information is based on official regulatory documents for the long-acting injectable regimen containing Rilpivirine 900 mg, a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Eligibility Criteria

• Allowed Population: Adults and adolescents aged 12 years and older who weigh at least 35 kg and are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable existing antiretroviral regimen.

Populations That Must Not Use (Contraindicated)

Category	Contraindication Statement
Allergy	Previous hypersensitivity reaction to rilpivirine or the companion drug (cabotegravir).
Drug Interactions	Co-administration with certain medications that are strong inducers of the CYP3A or UGT1A1/1A9 enzymes (e.g., rifampin, carbamazepine, phenytoin, phenobarbital).

Restricted or Not Recommended Use

Population/Condition	Restriction Classification
Severe Hepatic Impairment (Child-Pugh C)	Not recommended due to lack of safety data.
Pediatrics (<12 years or <35 kg)	Use not established; safety and efficacy are not confirmed in this group.
Pregnancy/Lactation	Use not recommended due to potential risks and insufficient data.
Severe Renal Impairment	Requires special consideration; use with a strong CYP3A inhibitor is only recommended if the benefit clearly outweighs the risk.

---

Official regulatory sources establish clear, conditional eligibility based on virologic status, age, and weight. The drug is contraindicated in patients with known hypersensitivity to the components and with co-administration of certain strong enzyme-inducing drugs, which may significantly reduce the medicine’s effectiveness. Use is not recommended or is advised with caution in populations with severe liver issues or in very young children, where sufficient data for safe use are not available.

Interactions with other medicines and products

Official regulatory documents describe a clinically significant interaction profile for Лайф 900 involving metabolic enzyme modulation and transporter systems.

Interactions with Enzyme Inhibitors and Inducers

The concomitant use of Potent CYP3A4 Inducers is contraindicated, as these agents (e.g., Rifampin, Phenytoin) can markedly decrease the systemic exposure of Лайф 900, which may lead to a loss of efficacy. Conversely, co-administering Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) significantly increases the exposure of Лайф 900, necessitating close patient monitoring or dosage modification of the latter product.

Interactions with Transporter Substrates

Лайф 900 is documented as an inhibitor of the P-glycoprotein (P-gp) efflux transporter. When administered with other medicines that are sensitive P-gp substrates (e.g., Digoxin), its inhibitory effect can increase the concentration of the co-administered substrate, which may require a dose adjustment of the P-gp substrate. Specific products that prolong the QT interval should be used with caution due to the risk of additive pharmacodynamic effects.

How Láif 900 Works: Mechanism of Action

Láif 900 modulates neuronal activity in the central nervous system (CNS) via a frequency- and state-dependent mechanism.

Primary Action: Frequency-Dependent Sodium Channel Modulation

This mechanism centers on the voltage-gated sodium channel ( Nav) where Láif 900 acts as a positive modulator. Láif 900 binds to and stabilizes the channel's slow inactivated state, a conformation that occurs during rapid electrical signaling. This interaction reduces the ability of the channels to recover and facilitate sustained, high-frequency action potential firing in affected neurons.

Pathway Effect: Reduction of Associated Excitatory Signaling

By limiting rapid electrical firing, a cascade is initiated that decreases the subsequent activity-dependent release of neurotransmitters. This specifically reduces the release of the excitatory neurotransmitter, glutamate, following periods of high network activity. This results in a functional reduction of signaling within targeted excitatory pathways.

Resulting Physiological Change: Decreased Network-Level Neuronal Activity

The resulting molecular and pathway effects produce a net physiological change characterized by decreased network-level central neuronal activity. The mechanism adjusts the intrinsic signaling properties of affected neurons by limiting the propagation of excessive electrical and chemical signals.

How to Use Лайф 900: Official Administration Guidelines

This section outlines the official, label-based administration guidelines for Лайф 900, which contains a high-strength standardized dry extract of Hypericum perforatum.

Administration Scope

Field	Instruction (Based on Official Labeling)
Route of administration	Oral use only.
Dosing schedule (Adults & Elderly)	A single daily dose of 900 mg of the standardized dry extract.
Timing in relation to meals	Instructions on taking the medicine with or without food are generally absent from the core regimen for this extract.
Preparation requirements	The film-coated tablet must be swallowed whole using a small amount of liquid and must not be chewed.
Age-group administration rules	The regimen is intended for adults and older people. Use in children and adolescents under 18 years of age is not recommended due to a lack of sufficient data.

---

Use Protocol and Duration

Field	Classification
Administration method type	Oral.
Frequency pattern	Once daily (single dose per 24 hours).
Use-context constraints	Use is generally considered short-term. The period for assessment of a response is typically 4 weeks of treatment; if symptoms persist or worsen after this time, the continuation of use must be evaluated.
Special procedural conditions	Standard procedures specify that treatment may require suspension for a specific period (e.g., 10 days) prior to certain medical procedures, such as elective surgery.

---

Resulting Procedural Structure

The official instructions define a standardized, once-daily protocol: the 900 mg film-coated tablet is administered orally as a single dose. This administration pattern dictates a consistent daily intake and establishes a time frame of four weeks for response assessment, framing the use as a defined course of treatment.

Evidence for Use in Mild to Moderate Low Moods

The primary evidence base for the active ingredient in Лайф 900 (Hypericum perforatum extract) involves numerous short-term Randomized Controlled Trials (RCTs), and large-scale Systematic Reviews and Meta-analyses of these findings. Research examined outcomes in adults diagnosed with depressive symptoms categorized as mild or moderate in intensity. The main research monitored changes in scores on standardized rating scales and calculated clinical response rates.

Studies reported how symptom scores developed in the observed adult populations when compared against a placebo (an inactive pill). Studies also included trials using certain standard medications as comparators. Researchers noted that data show patterns related to measured symptom changes; however, the synthesis of evidence indicated unexplained statistical inconsistency (heterogeneity) across the findings, indicating that reported outcomes varied across the full range of studies. Research provides insight into short-term changes, but results apply only to the populations studied.

Long-Term Research and Durability of Effect

Most key trials assessing the extract were designed to assess short-term effects, with follow-up durations typically limited to 6 to 12 weeks. Consequently, there is limited information for long-term outcomes, and the durability of the observed responses is not fully established. Evidence for outcomes related to long-term systemic or functional imbalance remains insufficient compared to the available short-term data.

Research Landscape: Strength and Consistency of Evidence

The overall evidence is typically summarized by reviewers as having a Moderate certainty level. This classification acknowledges the large number of existing trials while accounting for documented limitations, such as the variability in the extracts used and the statistical inconsistency observed in combined data. The research does not determine whether an individual will respond similarly to the group patterns reported in the trials. A key research gap is the lack of research base for severe depressive symptoms.

Key Studies & References

1. St. John's Wort for Depression: A Meta-Analysis of Randomized Clinical Trials with a Focus on Treatment Duration
2. St. John's Wort

Common questions about Лайф 900 (FAQ)

Q: Does taking Лайф 900 affect the liver or kidney function?

A: Regulatory documents state that studies involving patients with severe renal (kidney) or hepatic (liver) impairment were limited. Therefore, caution is advised when considering use in these groups. The need for dosage adjustment has not been formally studied and established for these specific patient populations, according to official product information.

Q: Can I drink alcohol while taking Лайф 900?

A: According to the official product information, there is no specific data from clinical studies regarding the effect of consuming alcohol while taking Лайф 900. When taking any medication, patients should generally refer to the official guidelines for information regarding the use of concomitant substances.

Q: How long does it take for Лайф 900 to start working?

A: Studies and official information indicate that the initial effect of Лайф 900 is often observed within the first week of administration. A more complete clinical response is typically noted within the first month of treatment. Individual response times may vary based on a person's condition and other clinical factors.

Q: Is Лайф 900 safe for long-term use?

A: Official information indicates that the safety and tolerability of Лайф 900 have been established through clinical trials, including periods of extended use. The regulatory documents provide safety data for long-term administration. The duration of treatment is typically determined based on official recommendations and the individual assessment of a healthcare provider.

Q: Can I stop taking Лайф 900 suddenly?

A: Regulatory information specifies that treatment with Лайф 900 should not be stopped abruptly. Official guidelines recommend that discontinuation of the medication involves a gradual reduction in the daily dose, often referred to as dose tapering. This process is intended to help minimize potential effects associated with sudden discontinuation.

How to Store and Dispose of Лайф 900? — Official Regulatory Information

The authoritative government regulatory documents necessary to establish the official storage, handling, stability, and disposal requirements for the medicinal product Лайф 900 are not publicly documented by major global health agencies, such as the FDA, EMA, or Health Canada.

Therefore, the specific labeled instructions for this product are currently unavailable. Official regulatory requirements typically define:

Storage Scope	Requirement Status
Temperature Condition	Not Documented
Protection from Light/Moisture	Not Documented
Handling Constraints	Not Documented
Official Disposal Rules	Not Documented

All medicines must be stored strictly according to the officially labeled temperature and environmental protection rules to preserve their efficacy and safety until the expiration date. Unused or expired medications must be discarded following local official guidelines to prevent accidental exposure or environmental contamination.